Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Fund and Insider Trading News: Crispin Odey, Paulson & Co., Point72 Asset Management, Acer Therapeutics Inc (ACER), Contango Oil & Gas (MCF), and More

Steve Cohen’s Point72 Is Exploring Raising Venture Fund (Bloomberg)
Steve Cohen’s Point72 Asset Management has discussed with clients the possibility of raising a venture fund at the same time he’s predicting lackluster returns for hedge funds. Cohen, who made his $10 billion fortune running a hedge fund, spent years building a team led by Matthew Granade to make venture investments with his personal wealth through a unit called Point72 Ventures. They’ve recently talked with prospective clients about adding a fund that would manage outside money, according to people with knowledge of the matter, who asked not to be identified because the discussions are private. The fund could exceed $750 million, one of the people said.

Detour Gold Denies Paulson’s Demand to Immediately Replace CEO (Reuters)
Nov 29 (Reuters) – Detour Gold Corp said on Thursday Chief Executive Officer Michael Kenyon will head the company until it finds a permanent replacement, pushing back against hedge fund Paulson & Co.’s demand to immediately replace him. Paulson & Co, which has a stake of about 6 percent in the miner, has pushed for Kenyon’s resignation, saying the company had “unsuccessfully tried to boost short-term performance” including “questionably running up its accounts payable to exaggerate cash flows”.

Insider Trading Eyeglasses

Alex Oakenman /

Crispin Odey’s Fund Among Winners as Intu Takeover Collapses (Bloomberg)

Hedge-fund manager Crispin Odey saw his bet against Intu Properties Plc pay off as a Brookfield Property Group venture abandoned its pursuit of the U.K. shopping-mall owner on Thursday. Intu plummeted by as much as 41 percent in London, the most since it started trading in 1992. The drop means a quick profit for short sellers. Odey Asset Management was the largest short seller betting against the company. A Barclays Plc filing disclosed wagers by a client totaling 0.6 percent of the company’s shares on Tuesday.

Exclusive: Elliott Steps in to Boost Arconic’s Sale Process – Sources (Reuters)
(Reuters) – Elliott Management Corp., the activist hedge fund that sits on Arconic Inc’s (ARNC.N) board, has stepped in to assume potential liabilities weighing on the sale process for the U.S. aluminum products maker, according to people familiar with the matter. Elliott’s move comes after Arconic rejected an acquisition offer of more than $11 billion from Apollo Global Management LLC (APO.N) as inadequate. Elliott hopes its intervention can help Arconic fetch a higher price, the sources said on Thursday.

‘Fundamentals Starting to Matter’ to Investors (Yahoo Finance)
Former hedge fund manager Whitney Tilson says the recent market shifts show investors are realizing there’s risk on Wall Street, and that’s presenting an opportunity for shorts. He spoke with Yahoo Finance’s Alexis Christoforous and Julia La Roche.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.